Squamous Cell Carcinoma Of The Head And Neck – Landscape & Forecast – Disease Landscape & Forecast

The treatment landscape for squamous cell carcinoma of the head and neck (SCCHN) witnessed a major change in 2019 with the approval of Merck & Co.’s Keytruda for untreated recurrent or metastatic SCCHN. For nearly a decade, the EGFR inhibitor Erbitux (Eli Lilly / Merck KGaA) was the cornerstone in the treatment algorithm. Immune checkpoint inhibitors (e.g., Keytruda, Bristol Myers Squibb / Ono Pharmaceutical’s Opdivo) are also prescribed in later lines, where competition is fierce. Although SCCHN has historically been a complex challenge for drug developers, many immuno-oncology treatment approaches and other drug classes are in the late-phase pipeline for both metastatic and early-stage settings. Several agents are positioned to treat the untapped and lucrative locoregionally advanced SCCHN, fueling market growth over the 2021-2031 forecast period.

Questions answered

  • What is the current treatment algorithm for locoregionally advanced and recurrent or metastatic SCCHN in the major pharmaceutical markets? What are interviewed experts’ views on current and emerging late-phase therapies?
  • How large are the clinically and commercially relevant drug-treatable SCCHN populations, and how will drug-treatment rates change over the 2021-2031 forecast period?
  • What market and patient share can agents in late-phase development for SCCHN expect to secure?
  • What are the key drivers of and constraints on the SCCHN therapy market, and how will these factors change over the 10-year forecast period?

Product description

Disease Landscape & Forecast provides comprehensive market intelligence with world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.

Solution enhancement

Disease Landscape & Forecast will feature continual updates in 2022 to provide timely insights and analyses as meaningful indication-specific news and events unfold.

Table of contents

  • Squamous Cell Carcinoma Of The Head And Neck - Landscape & Forecast - Disease Landscape & Forecast
    • Key findings
      • SCCHN - Key findings
    • Key updates
      • Q3 2022
        • September 2022
        • August 2022
      • Q2 2022
        • April 2022
      • Q1 2022
        • March 2022
        • February 2022
        • January 2022
      • Q4 2021
        • December 2021
        • November 2021
        • October 2021
      • Q3 2021
        • September 2021
        • August 2021
    • Market outlook
      • Key findings
        • Major-market share of SCCHN drug classes in 2021
        • Major-market share of SCCHN drug classes in 2031
        • Drug-treatable population share and major-market sales share in SCCHN in 2021
        • Drug-treatable population share and major-market sales share in SCCHN in 2031
        • Population positioning of therapies in SCCHN
        • SCCHN SWOT analysis
      • Market drivers and constraints
        • What factors are driving the market for SCCHN?
        • What factors are constraining the market for SCCHN?
        • Major-market sales for SCCHN by region: 2021-2031
        • Major-market sales for SCCHN by drug class: 2021-2031
        • Major-market sales of key therapies for SCCHN: 2021-2031
      • Segment-specific trends
        • Patient-share dynamics of key treatments for locoregionally advanced non-nasopharyngeal SCCHN in the United States: 2021-2031
        • Major-market shares of drug classes for locoregionally advanced non-nasopharyngeal SCCHN: 2021-2031
        • Patient-share dynamics of key treatments for first-line non-nasopharyngeal SCCHN in the United States: 2021-2031
        • Patient-share dynamics of key treatments for first-line nasopharyngeal SCCHN in the United States: 2021-2031
        • Major-market shares of drug classes for first-line non-nasopharyngeal SCCHN: 2021-2031
        • Major-market shares of drug classes for first-line nasopharyngeal SCCHN: 2021-2031
        • Patient-share dynamics of key treatments for second-line non-nasopharyngeal SCCHN in the United States: 2021-2031
        • Patient-share dynamics of key treatments for second-line nasopharyngeal SCCHN in the United States: 2021-2031
        • Patient share dynamics of key therapies in third-line non-nasopharyngeal SCCHN in the United States: 2021-2031
        • Patient share dynamics of key therapies in third-line nasopharyngeal SCCHN in the United States: 2021-2031
        • Major-market shares of drug classes for second-line non-nasopharyngeal SCCHN: 2021-2031
        • Major-market shares of drug classes for third-line non-nasopharyngeal SCCHN: 2021-2031
        • Major-market shares of drug classes for second-line nasopharyngeal SCCHN: 2021-2031
        • Major-market shares of drug classes for third-line nasopharyngeal SCCHN: 2021-2031
    • Forecast
      • Market Forecast Assumptions
      • Market Forecast Dashboard
    • Etiology and pathophysiology
      • Disease overview
        • Disease pathophysiology
          • Anatomy, development, and progression of SCCHN
          • Anatomy, development, and progression of SCCHN
          • Risk factors associated with SCCHN
          • Risk factors associated with SCCHN
        • Staging and classification
          • Clinical staging of SCCHN
          • Definition of TNM staging classification for oral cavity SCCHN
          • Definition of TNM staging classification of hypopharyngeal SCCHN
          • Definition of TNM staging classification of laryngeal SCCHN
          • TNM staging system for classification of oral cavity, hypopharyngeal, and laryngeal SCCHN
          • Definition of TNM staging classification for oropharyngeal SCCHN
          • TNM staging system for the classification of oropharyngeal SCCHN
          • Definition of TNM staging classification of nasopharyngeal SCCHN
          • TNM staging system for classification of nasopharyngeal SCCHN
          • Composite TNM staging and treatment overview of SCCHN
        • Key pathways and drug targets
          • Key pathways and drug targets in SCCHN
          • Immune checkpoint activation and pathways
      • Epidemiology
        • Key findings
          • Epidemiology populations
            • Disease definition
            • Methods
            • Sources used for diagnosed incidence of squamous cell carcinoma of the head and neck
            • Diagnosed incident cases of squamous cell carcinoma of the head and neck: 2021-2031
            • Diagnosed incident cases of squamous cell carcinoma of the head and neck by site (nasopharyngeal vs. non-nasopharyngeal): 2021-2031
            • Disease definition
            • Methods
            • Sources used for stage distribution of squamous cell carcinoma of the head and neck
            • Diagnosed incident cases of nasopharyngeal squamous cell carcinoma of the head and neck by stage: 2021-2031ttttt
            • Diagnosed incident cases of non-nasopharyngeal squamous cell carcinoma of the head and neck by stage: 2021-2031ttt
            • Disease definition
            • Methods
            • Sources used for metastatic recurrent incident cases of squamous cell carcinoma of the head and neck
            • Metastatic recurrent incident cases of squamous cell carcinoma of the head and neck: 2021-2031
            • SCCHN patient flow
            • Sources used for drug-treatable populations of SCCHN
            • Drug-treatable cases of SCCHN (all histologies): 2021-2031
            • Drug-treatable cases of non-nasopharyngeal SCCHN: 2021-2031
            • Drug-treatable cases of nasopharyngeal SCCHN: 2021-2031
            • Sources used for drug-treated SCCHN populations
            • Drug-treated cases of SCCHN (all histologies): 2021-2031
            • Drug-treated cases of non-nasopharyngeal SCCHN: 2021-2031
            • Drug-treated cases of nasopharyngeal SCCHN: 2021-2031
        • Current treatment
          • Key findings
            • Treatment goals
              • Key endpoints used in clinical trials for SCCHN
            • Key current therapies
              • Overview
              • Current treatments used for SCCHN
              • Recent market events influencing the use of key current therapies in SCCHN
              • Mechanism of action of key current drugs used for SCCHN
              • Key results from select clinical trials investigating Erbitux for the treatment of SCCHN
              • Ongoing clinical development of Erbitux
              • Key ongoing clinical trials of Erbitux in the treatment of SCCHN
              • Expert insight: Erbitux
              • Key results from select clinical trials investigating Keytruda for the treatment of SCCHN
              • Ongoing clinical development of Keytruda
              • Key ongoing clinical trials of Keytruda in the treatment of SCCHN
              • Expert insight: Keytruda
              • Key results from select clinical trials investigating Opdivo for SCCHN
              • Ongoing clinical development of Opdivo
              • Key ongoing clinical trials of Opdivo in the treatment of SCCHN
              • Expert insight: Opdivo
              • Key results from select clinical trials investigating Steboronine for the treatment of SCCHN
              • Ongoing clinical development of Steboronine
              • Expert insight: Steboronine
              • Key results from select clinical trials investigating Akalux for the treatment of SCCHN
              • Ongoing clinical development of Akalux
              • Key ongoing clinical trials of Akalux in the treatment of SCCHN
              • Expert insight: Akalux
            • Medical practice
              • Early-stage localized (stage I/II) SCCHN
              • Locoregionally advanced (stage III/IVA/IVB) SCCHN
              • First-line recurrent or metastatic SCCHN
              • Second- and third-line recurrent or metastatic SCCHN
              • Treatment guidelines
              • Patient characteristics influencing drug selection in SCCHN
              • Treatment decision tree for early-stage localized (stage I/II) SCCHN
              • Treatment decision tree for locoregionally advanced (stage III/IVA/IVB) SCCHN
              • Treatment decision tree for recurrent or metastatic SCCHN
          • Unmet need overview
            • Current and future attainment of unmet needs in SCCHN
            • Top unmet needs in SCCHN: current and future attainment
          • Emerging therapies
            • Key findings
              • Key emerging therapies
                • Key therapies in development for SCCHN
                • Estimated market authorization dates of key emerging therapies for the treatment of SCCHN
                • Key results from select clinical trials investigating Yervoy for the treatment of SCCHN
                • Analysis of clinical development program for Yervoy
                • Key ongoing clinical trials of Yervoy in the treatment of SCCHN
                • Expectations for market authorization and sales opportunity of Yervoy in SCCHN
                • Key results from select clinical trials investigating Tecentriq for the treatment of SCCHN
                • Analysis of clinical development program for Tecentriq
                • Key ongoing clinical trials of Tecentriq in the treatment of SCCHN
                • Expert insights: Tecentriq
                • Expectations for the market authorization and sales opportunity of Tecentriq in SCCHN
                • Key results from select clinical trials investigating Toripalimab for the treatment of SCCHN
                • Analysis of clinical development program for Toripalimab
                • Key ongoing clinical trials of Toripalimab in the treatment of SCCHN
                • Expert insight: toripalimab
                • Expectations for the market authorization and sales opportunity of toripalimab in SCCHN
                • Key results from select clinical trials investigating Penpulimab for the treatment of SCCHN
                • Analysis of the clinical development program for Penpulimab
                • Key ongoing clinical trials of Penpulimab in the treatment of SCCHN
                • Expectations for the market authorization and sales opportunity of Penpulimab in SCCHN
                • Key results from select clinical trials investigating Rovaleucel for the treatment of SCCHN
                • Analysis of the clinical development program for Rovaleucel
                • Key ongoing clinical trials of Rovaleucel in the treatment of SCCHN
                • Expert insight: Rovaleucel
                • Expectations for the market authorization and sales opportunity of Rovaleucel in SCCHN
                • Key results from select clinical trials investigating Multikine for the treatment of SCCHN
                • Analysis of the clinical development program for Multikine
                • Expert insight: Multikine
                • Expectations for the market authorization and sales opportunity of Multikine in SCCHN
                • Key results from select clinical trials investigating Lenvima for the treatment of SCCHN
                • Analysis of the clinical development program for Lenvima
                • Key ongoing clinical trials of Lenvima in the treatment of SCCHN
                • Expert insight: Lenvima
                • Expectations for the market authorization and sales opportunity of Lenvima in SCCHN
                • Key results from select clinical trials investigating Xevinapant for the treatment of SCCHN
                • Analysis of the clinical development program for Xevinapant
                • Key ongoing clinical trials of Xevinapant in the treatment of SCCHN
                • Expert insight: Xevinapant
                • Expectations for market authorization and sales opportunity of Xevinapant in SCCHN
                • Key results from select clinical trials investigating Buparlisib for the treatment of SCCHN
                • Analysis of the clinical development program for Buparlisib
                • Key ongoing clinical trials of Buparlisib in the treatment of SCCHN
                • Expert insight: Buparlisib
                • Expectations for market authorization and sales opportunity of Buparlisib in SCCHN
                • Key results from select clinical trials investigating Tipifarnib for the treatment of SCCHN
                • Analysis of the clinical development program for Tipifarnib
                • Key ongoing clinical trials of Tipifarnib in the treatment of SCCHN
                • Expert insight: Tipifarnib
                • Expectation for market authorization and sales opportunity of Tipifarnib in SCCHN
              • Early-phase pipeline analysis
              • Access and reimbursement overview
                • Region-specific reimbursement practices
                  • Key market access considerations in SCCHN: United States
                  • General reimbursement environment: United States
                  • Key market access considerations in SCCHN: EU5
                  • General reimbursement environment: EU5
                  • Key market access considerations in SCCHN: Japan
                  • General reimbursement environment: Japan
              • Appendix
                • SCCHN bibliography
                • Abbreviation

            Login to access report

            launch Related Market Assessment Reports